Singapore-based AUM Biosciences partners with Roche for cancer drug trial
11 May 2022 | News
AUM Biosciences partners with Roche for development of AUM001 in combination with anti-PD-L1 therapy in solid tumor indications
Image credit: shutterstock
Singapore-based AUM Biosciences has entered into a clinical trial collaboration and supply agreement with Roche to evaluate AUM001, the company’s novel, highly selective MNK1/2 inhibitor, in combination with atezolizumab (Tecentriq), Roche’s anti-PD-L1 therapy, across multiple solid tumor indications, leading with Non-Small Cell Lung Cancer (NSCLC) and Urothelial Cancer (UC).
As a monotherapy, AUM001 demonstrated excellent safety, tolerability, and target engagement in two Phase 1 studies. In a multiple ascending dose Phase 1 trial completed in March 2021, there were no Grade 3/4 treatment emergent AEs or dose limiting toxicities (DLTs).
“Targeted immunotherapies have improved overall survival in a segment of patients with advanced or metastatic cancers. However, there remains a critical need for novel clinical therapies that can further prolong survival in checkpoint inhibitor responsive patients as well as make unresponsive patients responsive AUM001 has a unique proposition where we anticipate preventing or delaying T-cell exhaustion as well as potently stimulating the innate immune system will lead to superior outcomes for cancer patients,” noted Harish Dave, MB, ChB, MBA, CMO of AUM Biosciences.
Tecentriq (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group.
